SMTI vs BLCO

For growth investors, Sanara MedTech Inc.

(SMTI) is the stronger pick with 19. 0% revenue growth year-over-year, versus 6. 5% for Bausch + Lomb Corporation (BLCO). Analysts rate Sanara MedTech Inc. (SMTI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Bausch + Lomb Corporation (BLCO) delivered a total return of -20.

5%, compared to -28. 3% for Sanara MedTech Inc. (SMTI). Over 10 years, the gap is even starker: SMTI returned +218. 0% versus BLCO's -20. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bausch + Lomb Corporation (BLCO) is the lower-risk stock at 1.

39β versus Sanara MedTech Inc. 's 1. 42β — meaning SMTI is approximately 2% more volatile than BLCO relative to the S&P 500. On balance sheet safety, Bausch + Lomb Corporation (BLCO) carries a lower debt/equity ratio of 82% versus 8% for Sanara MedTech Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanara MedTech Inc.

(SMTI) is pulling ahead at 19. 0% versus 6. 5% for Bausch + Lomb Corporation (BLCO). On earnings-per-share growth, the picture is similar: Bausch + Lomb Corporation grew EPS -13. 3% year-over-year, compared to -282. 5% for Sanara MedTech Inc.. Over a 3-year CAGR, SMTI leads at 31. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bausch + Lomb Corporation (BLCO) is the more profitable company, earning -7.

1% net margin versus -36. 4% for Sanara MedTech Inc. — meaning it keeps -7. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SMTI leads at 7. 1% versus 3. 7% for BLCO. At the gross margin level — before operating expenses — SMTI leads at 92. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bausch + Lomb Corporation (BLCO) trades at 20.

1x forward P/E versus 165. 9x for Sanara MedTech Inc. — 145. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SMTI: 67. 7% to $32. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sanara MedTech Inc.

(SMTI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+218. 0% 10Y return). Both have compounded well over 10 years (SMTI: +218. 0%, BLCO: -20. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SMTI is a small-cap high-growth stock; BLCO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.